Suggested Topics within your search.
Showing 1,041 - 1,060 results of 2,480 for search '"antigen"', query time: 0.06s Refine Results
  1. 1041

    Alternanthera mosaic potexvirus: Several Features, Properties, and Application by Ekaterina Donchenko, Ekaterina Trifonova, Nikolai Nikitin, Joseph Atabekov, Olga Karpova

    Published 2018-01-01
    “…Furthermore, AltMV virions and VLPs demonstrate high immunogenicity, enhancing the immune response to the target antigen thus offering the possibility of being used as potential adjuvants. …”
    Get full text
    Article
  2. 1042

    A Case of Immunotherapy-Induced Colitis Complicated by Perforation and Treated with Infliximab Postoperatively by Lukas Delasos, Aakash Desai, Nerea Lopetegui Lia, Nikhila Kethireddy, Carolyn Ray

    Published 2019-01-01
    “…Severe colitis has been reported in approximately 5% of patients treated with cytotoxic T-lymphocyte-associated antigen-4 (CTLA-4) inhibitors, such as ipilimumab. …”
    Get full text
    Article
  3. 1043

    A case of plasmacytoma with widespread metastasis in a dog by Osman Dagar, Aysenur Tural, Zeynep Celik, Fatih Mehmet Ozturk, Mehmet Tuzcu, Erhan Gulcicek

    Published 2023-12-01
    “…In addition, in the immunohistochemical staining of lung, liver, spleen, pancreas, mediastinal and mesenterial lymph nodes, intestine and kidney sections with Proliferating Cell Nuclear Antigen (PCNA) antibody, severe immunoreactivity was detected in tumor cells. …”
    Get full text
    Article
  4. 1044

    Induction of Tolerance via the Sublingual Route: Mechanisms and Applications by Philippe Moingeon, Laurent Mascarell

    Published 2012-01-01
    “…The oral immune system comprises various antigen-presenting cells, including Langerhans cells, as well as myeloid and plasmacytoid dendritic cells (DCs) with a distinct localisation in the mucosa, along the lamina propria and in subepithelial tissues, respectively. …”
    Get full text
    Article
  5. 1045

    Major Histocompatibility Complex Genes as Therapeutic Opportunity for Immune Cold Molecular Cancer Subtypes by Paweł Karpiński, Łukasz Łaczmański, Maria M. Sąsiadek

    Published 2020-01-01
    “…Current immunotherapies are effective only in a subset of patients, likely due to several factors including defects in tumor cell antigen presentation, decreased response to immune effectors, and molecular heterogeneity of cancers. …”
    Get full text
    Article
  6. 1046

    The Molecular Imaging of Natural Killer Cells by Mariya Shapovalova, Sean R. Pyper MD, PhD, Branden S. Moriarity PhD, Aaron M. LeBeau PhD

    Published 2018-09-01
    “…Unlike T cells, they do not require human leukocyte antigen (HLA) matching allowing for the adoptive transfer of allogeneic NK cells in the clinic. …”
    Get full text
    Article
  7. 1047

    Hsp70 and Its Molecular Role in Nervous System Diseases by Giuseppina Turturici, Gabriella Sconzo, Fabiana Geraci

    Published 2011-01-01
    “…Hsp70 functions as a chaperone and protects neurons from protein aggregation and toxicity (Parkinson disease, Alzheimer disease, polyglutamine diseases, and amyotrophic lateral sclerosis), protects cells from apoptosis (Parkinson disease), is a stress marker (temporal lobe epilepsy), protects cells from inflammation (cerebral ischemic injury), has an adjuvant role in antigen presentation and is involved in the immune response in autoimmune disease (multiple sclerosis). …”
    Get full text
    Article
  8. 1048

    Tumor cells escape immunosurveillance by hampering LFA-1 by Shishir Upadhyay, Lewis Murugu, Lena Svensson, Lena Svensson

    Published 2025-01-01
    “…Integral to this process is the integrin Lymphocyte Function-Associated Antigen 1 (LFA-1). LFA-1 facilitates adhesion during leukocyte migration and helps establish stable cell-to-cell contacts between leukocytes and their targets. …”
    Get full text
    Article
  9. 1049

    Toll-Like Receptor-Based Strategies for Cancer Immunotherapy by Saghar Pahlavanneshan, Ali Sayadmanesh, Hamidreza Ebrahimiyan, Mohsen Basiri

    Published 2021-01-01
    “…These strategies include systemic administration of TLR antagonist along with immune cell transfer and also genetic engineering of the immune cells using TLR signaling components to improve the function of genetically engineered immune cells such as chimeric antigen receptor-modified T cells. Here, we explore the current status of the cancer immunotherapy approaches based on manipulation of TLR signaling to provide a perspective of the underlying rationales and potential clinical applications. …”
    Get full text
    Article
  10. 1050

    Both Maturation and Survival of Human Dendritic Cells are Impaired in the Presence of Anergic/Suppressor T Cells by L. Frasca, C. Scottà, G. Lombardi, E. Piccolella

    Published 2003-01-01
    “…Mouse anergic T cells were shown to suppress responder T cell activation by inhibiting the antigen presenting function of DC. In the present work we studied the effects of co-culturing human anergic CD4+ T cells with autologous dendritic cells (DC) at different stages of maturation. …”
    Get full text
    Article
  11. 1051

    Adverse Immunologically Mediated Oral Mucosal Reactions to Systemic Medication: Lichenoid Tissue Reaction/Interface Dermatitis-Stomatitis, Autoimmune Vesiculobullous Disease, and I... by R. A. G. Khammissa, R. Chandran, A. Masilana, J. Lemmer, L. Feller

    Published 2018-01-01
    “…The type of hypersensitivity immune response generated, whether antibody mediated or T cell mediated, or an immune complex reaction is determined by multiple factors, including the molecular characteristics of the allergen, the route of administration of the medication, the manner of presentation of the allergen by antigen-presenting cells to naïve T cells, the repertoire of the T cell receptors, and the cytokine profile within the microenvironment. …”
    Get full text
    Article
  12. 1052

    Anti-CCP: History and its Usefulness by M. Herold, V. Boeser, E. Russe, W. Klotz

    Published 2005-01-01
    “…All three CCP2 assays show similar results as all CCP2 assays use the same antigen-coated plates. This study was an evaluation of a new automated method for the determination of anti-CCP2 in a routine laboratory setting. …”
    Get full text
    Article
  13. 1053

    Eosinophilic esophagitis: literature review and original case presentation by V. T. Ivashkin, Ye. K. Baranskaya, V. O. Kaybysheva, Ye. V. Ivanova, Ye. D. Fedorov

    Published 2012-02-01
    “…Eosinophilic esophagitis is chronic immune antigen-mediated inflammatory disease of the esophagus with still obscure etiopathogenesis. …”
    Get full text
    Article
  14. 1054

    A replication-incompetent adenoviral vector encoding for HSV-2 gD2 is immunogenic and protective against HSV-2 intravaginal challenge in mice. by Elisa Rossetti, Marija Vujadinovic, Ella van Huizen, Jeroen Tolboom, Hanneke Schuitemaker, Feng Yao, Roland Zahn, Eirikur Saeland

    Published 2024-01-01
    “…We have designed an adenoviral vector type 35 (Ad35)-based vaccine encoding the HSV-2 major surface antigen gD2 (Ad35.HSV.gD2). Immunization of mice with Ad35.HSV.gD2 elicited virus neutralizing antibody titers (VNT) and cellular responses against HSV-2 and HSV-1. …”
    Get full text
    Article
  15. 1055

    COSMC-Regulated O-Glycosylation: A Bioinformatics-Driven Biomarker Identification for Stratifying Glioblastoma Stem Cell Subtypes by Sara Sadat Aghamiri, Rada Amin

    Published 2024-12-01
    “…High Cosmc expression also enriched immune-related pathways, including inflammatory response and antigen presentation, and was associated with presence of myeloid cells, T cells, and NK cells. …”
    Get full text
    Article
  16. 1056

    Current status and innovative developments of CAR-T-cell therapy for the treatment of breast cancer by Hany E. Marei, Khaled Bedair, Anwarul Hasan, Layla Al-Mansoori, Sara Caratelli, Giuseppe Sconocchia, Alice Gaiba, Carlo Cenciarelli

    Published 2025-01-01
    “…We discuss in detail the role of tumor-associated antigens in breast cancer, current clinical trials, barriers to the intended therapeutic effects of CAR-T cell therapy, and potential ways to increase treatment efficacy. …”
    Get full text
    Article
  17. 1057

    CAR-T cell therapy in developing countries: how long should we wait? by Om P Kurmi, Ramila Shilpakar, Sanjivan Gautam, Balram Gautam, Sudhamshu K C

    Published 2024-12-01
    “…However, the survival rates for patients with cancer in these regions are notably lower than those in high-income countries, primarily due to late diagnosis and limited access to advanced treatments. Chimeric antigen receptor (CAR) T-cell therapy has demonstrated promising outcomes in certain terminally ill patients with cancer, yet access to this treatment remains limited in LMICs, including Nepal.The Center for Regenerative Medicine in Nepal has initiated efforts to make CAR-T cell therapy accessible to patients with cancer at a substantially reduced cost. …”
    Get full text
    Article
  18. 1058

    Immunodiffusion assay as a method of bovine leucosis post-mortem diagnosis by A. R. Mustafayev

    Published 2022-03-01
    “…The proposed method allows for the detection of antibodies against bovine leukemia virus (BLV) antigen located in the muscle and tissue fluids (plasma and lymph) of meat and offal. …”
    Get full text
    Article
  19. 1059

    An Overview of the Role of Innate Lymphoid Cells in Gut Infections and Inflammation by Silvia Sedda, Irene Marafini, Michele M. Figliuzzi, Francesco Pallone, Giovanni Monteleone

    Published 2014-01-01
    “…Innate lymphoid cells (ILCs) are a group of hematopoietic cells devoid of antigen receptors that have important functions in lymphoid organogenesis, in the defense against extracellular pathogens, and in the maintenance of the epithelial barrier. …”
    Get full text
    Article
  20. 1060

    Immunomodulatory Effects of Hemagglutinin- (HA-) Modified A20 B-Cell Lymphoma Expanded as a Brain Tumor on Adoptively Transferred HA-Specific CD4+ T Cells by Valentin P. Shichkin, Roman M. Moriev

    Published 2014-01-01
    “…Previously, the mouse A20 B-cell lymphoma engineered to express hemagglutinin (HA) antigen (A20HA) was used as a systemic tumor model. …”
    Get full text
    Article